Here are six articles published by Becker's Hospital Review this week highlighting Medtronic's divestiture of its medical supplies unit and a drug company CEO's views on price hikes, among other topics.
1. Supply chain tip of the week: Choosing the right waste management model
As medical waste service providers increasingly insist on hospitals moving to an integrated waste stream pricing model, hospitals should consider implications that can arise from this practice, according to Eric Slimp, manager of purchased services for MD Buyline.
2. Drug shortages raise price of alternative treatments: 4 study findings
Low supplies of prescription drugs not only complicate patient care, they also make it more expensive, according to a new study published in the New England Journal of Medicine.
3. Medtronic sells majority of medical supplies unit to Cardinal for $6.1B
Minneapolis-based Medtronic will sell part of its patient monitoring and recovery unit to Dublin, Ohio-based Cardinal Health for $6.1 billion in cash.
4. Lannett CEO gloats about generic price hikes, investors say
Federal investigations and public scrutiny over high drug prices won't stop Arthur Bedrosian, CEO of Lannett Co., from raising prices.
5. PBM lobby group: No correlation between drug prices and rebates
A new market analysis from Visante shows no relationship between drug prices and the amount of rebates and discounts pharmacy benefit manufacturers negotiate with drugmakers.
6. Hyland's recalls teething products months after FDA warns of toxic substances
Hyland's Homeopathic on April 14 issued a recall of its baby teething tablets about three months after the Food and Drug Administration discovered inconsistent amounts of the toxic substance belladonna in the products.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
FDA OKs Tecentriq for advanced bladder cancer
Bristol-Myers will license drugs to Biogen, Roche for $470M